Tariff worries continue hanging over companies as they report their latest financial results and try to provide guidance on ...

During a Q1 earnings call, Merck CEO Rob Davis discussed pipeline diversification plans and effects of tariffs on its ...

Halozyme is not holding back against Merck & Co. in the companies' injectable Keytruda patent dispute, having now escalated a verbal warning into a lawsuit. | Halozyme is not holding back against ...

Revenue for Q1 2025 reached $15.5 billion, driven by robust performances in oncology, animal health, and new product launches. The company reaffirmed its focus on research and development as a key ...

Siren said proceeds will go toward investigational new drug (IND)-enabling animal studies and clinical-grade production of therapy. Upon FDA approval of an IND application, Siren plans to start on ...

Merck’s first-quarter net income increased as sales of its Keytruda cancer drug rose, but the Big Pharma company cut its 2025 ...

The drugmaker absorbed additional tariff-related costs in the first quarter, but has taken steps to lower the financial impact it’ll have for the rest of the year and beyond.

The company’s stock fell as much as 2.8% after markets opened in New York Thursday. For the first quarter, Merck’s results ...

U.S. pharmaceutical giant Merck has warned that existing tariffs imposed by the Trump administration will cost the company an ...

With potential tariffs and other drug pricing policies on the horizon, the industry is navigating uncertain waters. | The ...

Major drugmakers like Bristol Myers Squibb, Merck & Co, Sanofi, and Roche are preparing for possible tariffs on the ...